Scientists Develop Bacteria-Inspired Cancer Therapy That Targets Tumor Cells’ Energy Source

Researchers at the University of Illinois Chicago have unveiled a promising new cancer treatment approach inspired by bacteria naturally found inside tumors, offering a potentially innovative strategy for slowing cancer growth.

Rather than attacking cancer cells directly in the conventional way, the new therapy focuses on disrupting how tumor cells generate energy, effectively weakening them from within.

The treatment showed particularly strong results in prostate cancer models, where researchers found it became even more effective when combined with radiation therapy, one of the most widely used cancer treatment methods.

According to the study, tumor growth slowed significantly when both treatments were used together, suggesting the new approach could enhance the effectiveness of existing cancer therapies. At the center of the breakthrough is a laboratory-engineered peptide known as aurB, which was developed from a bacterial protein.

Once introduced into cancer cells, aurB targets the mitochondria—the structures responsible for producing energy needed for cell survival and growth. By disrupting mitochondrial function, the peptide essentially cuts off the energy supply cancer cells rely on to multiply rapidly. Without sufficient energy, tumor cells become less capable of surviving, dividing, and spreading.

Senior author Tohru Yamada, an associate professor in the departments of surgery and biomedical engineering at the University of Illinois Chicago and a member of the University of Illinois Cancer Center, explained that mitochondria are critical to cell survival and therefore represent an attractive target for cancer treatment.

He noted that many cancer cells display abnormal mitochondrial activity and often contain increased numbers of mitochondria because of their aggressive growth demands. Since cancer cells require enormous amounts of energy to sustain rapid expansion, interfering with their energy production could offer a highly strategic way to suppress tumor progression.

Scientists have long known that bacteria can exist within tumors as part of what is known as the tumor microenvironment. In recent years, this discovery has sparked growing scientific interest in understanding whether these microorganisms can be harnessed for therapeutic purposes.

This latest research builds on that idea by using bacterial biology not as a direct weapon against cancer, but as inspiration for creating compounds capable of exploiting cancer cells’ vulnerabilities.

While the treatment remains in the research stage and further studies are needed before human clinical use, the findings add to a growing body of evidence suggesting that future cancer therapies may increasingly target metabolism and cellular energy systems.

The study also reflects a broader shift in oncology research toward more precise and biologically informed treatments designed to weaken cancer through its internal dependencies rather than relying solely on traditional cell-killing methods.

As cancer research continues to evolve, innovations like aurB could eventually open the door to new therapies that are more targeted, potentially more effective, and better suited to work alongside standard treatments such as radiation and chemotherapy.